Pazopanib HCl (GW786034 HCl) , ≥98% , 635702-64-6

Synonym(s):
5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide hydrochloride;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, hydrochloride

CAS NO.：635702-64-6

Empirical Formula: C21H23N7O2S.ClH

Molecular Weight: 473.987

MDL number: MFCD12546138

EINECS: 619-728-0

Pack Size	Price	Stock	Quantity
25MG	RMB95.20	In Stock
250MG	RMB124.00	In Stock
100MG	RMB263.20	In Stock
1G	RMB291.20	In Stock
others			Enquire

Update time: 2022-07-08

PRODUCT Properties

Melting point:	>290°C (dec.)
storage temp.	Hygroscopic, Refrigerator, under inert atmosphere
solubility	Acetonitrile (Slightly), DMSO (Slightly)
form	Yellow powder.
color	White to Off-White
Stability:	Hygroscopic
InChIKey	MQHIQUBXFFAOMK-UHFFFAOYSA-N
SMILES	CC1N(N=C2C=C(N(C3C=CN=C(NC4C=CC(C)=C(S(=O)(=O)N)C=4)N=3)C)C=CC=12)C.Cl

Description and Uses

Pazopanib Hydrochloride is the hydrochloride salt of a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is an oral second-generation multitarget TKI developed by GSK and approved for marketing by the FDA in 2009 and the EMA in 2010. It targets the VEGFR, platelet-derived growth factor receptor, and c-kit, key proteins responsible for tumor growth and survival. It is used to treat patients with advanced RCC and advanced soft tissue sarcoma who have experienced chemotherapy. Pazopanib Hydrochloride has a role as an antineoplastic agent, a vascular endothelial growth factor receptor antagonist, a tyrosine kinase inhibitor, and an angiogenesis-modulating agent.

The Hydrochloride salt of Pazopanib (P210925) a oral angiogenesis inhibitor targeting VEGFR and PDGFR.